A metal-organic framework-based immunomodulatory nanoplatform for anti-atherosclerosis treatment
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.01.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Zhijue Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Atherosclerosis, Plaque, Atherosclerotic. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Immunomodulatory therapy has become a promising method for the clinical treatment of many diseases. Recently, pilot studies revealed that immunomodulatory therapy exhibited good effects on the treatment of cardiovascular diseases, but many problems remain to be solved, such as useful platforms for drug co-delivery and combination therapies. In this study, we designed and constructed the multifunctional nanoparticle Rapa@UiO-66-NH-FAM-IL-1Ra (RUFI) for the treatment of atherosclerotic cardiovascular disease. This nanoplatform combined the advantages of metal-organic frameworks (MOFs) for drug co-delivery, rapamycin and IL-1Ra for immunomodulation, IL-1Ra for cellular targeting, and 5-FAM for fluorescence imaging. RUFI exhibited good drug release of rapamycin and IL-1Ra and specific cytotoxicity for inflammatory macrophages in vitro. In an atherosclerotic model of diet-fed ApoE-/- mice, RUFI significantly targeted and reduced atherosclerosis plaques in coronary arteries, carotid arteries, and aortas. Mechanistic studies indicated that RUFI modulated macrophage phenotype, cytokine expression, and autophagy. This study demonstrated that combination therapy with rapamycin and IL-1Ra via MOF carriers enhanced the immunoregulatory effects against atherosclerosis. This drug co-delivery system suggests that MOF carriers loaded with immunomodulators are promising treatments for atherosclerosis or other inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
- Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Electronic address: ykaichuang@163.com.
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China; Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical U…
- Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Electronic address: luxinwu@shsmu.edu.cn.
- Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Electronic address: boli@shsmu.edu.cn.
Zitieren
APA
Xu, Z., Wu, Z., Huang, S., Ye, K., Jiang, Y., Liu, J., Liu, J., Lu, X., & Li, B. (2023). A metal-organic framework-based immunomodulatory nanoplatform for anti-atherosclerosis treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.01.024
Vancouver
Xu Z, Wu Z, Huang S, Ye K, Jiang Y, Liu J, et al. A metal-organic framework-based immunomodulatory nanoplatform for anti-atherosclerosis treatment. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.01.024
BibTeX
@article{Xu2023,
author = {Xu, Zhijue and Wu, Zhaoyu and Huang, Sheng and Ye, Kaichuang and Jiang, Yihong and Liu, Jianqiang and Liu, Junchao and Lu, Xinwu and Li, Bo},
title = {A metal-organic framework-based immunomodulatory nanoplatform for anti-atherosclerosis treatment},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.01.024}
}
EUVIMED